Instruction for use: Ribomunyl

Dosage form: Granules for solution for oral administration; tablets

ATX

L03AX Other immunostimulants

Pharmacological group:

Other immunomodulators

The nosological classification (ICD-10)

H66 Purulent and unspecified otitis media: Bacterial ear infections; Inflammation of the middle ear; Infections of ENT organs; Infectious-inflammatory disease of ENT organs; Infectious and inflammatory diseases of ENT organs; Infectious-inflammatory diseases of the ear; Infectious diseases of ENT organs with severe pain syndrome; Ear infection; Otitis media is infectious; Persistent middle ear inflammation in children; Ear pain with otitis

H70 Mastoiditis and related conditions: Mastoiditis

J01 Acute sinusitis: Inflammation of the paranasal sinuses; Inflammatory diseases of the paranasal sinuses; Purulent-inflammatory processes of the paranasal sinuses; Infectious-inflammatory disease of ENT organs; Infection of the paranasal sinuses; Combined sinusitis; Exacerbation of sinusitis; Acute inflammation of the paranasal sinuses; Acute bacterial sinusitis; Acute sinusitis in adults; Subacute sinusitis; Sinusitis acute; Sinusitis

J02.9 Acute pharyngitis, unspecified: Purulent pharyngitis; Acute rhinopharyngitis; Lymphonodular pharyngitis

J03.9 Acute tonsillitis, unspecified (angina agranulocytic): Throat infections; Acute tonsillitis; Angina; Follicular tonsillitis; Angina alimentary-hemorrhagic; Secondary sore throat; Sore throat primary; Angina follicular; Angina; Inflammatory diseases of the tonsils; Catarrhal angina; Lacunar angina; Acute Sore Throat; Tonsillitis; Tonsillitis acute; Tonsillar angina; Follicular sore throat; Bacterial tonsillitis

J04 Acute laryngitis and tracheitis: Cough in diseases of the upper respiratory tract; Laryngitis; Laryngitis acute; Tracheitis acute; Pharyngolaryngitis; Infectious-inflammatory disease of ENT organs

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J18 Pneumonia without specification of pathogens: Alveolar pneumonia; Community-acquired pneumonia atypical; Community-acquired pneumonia non-pneumococcal; Pneumonia; Inflammation of the lower respiratory tract; Inflammatory lung disease; Shared pneumonia; Respiratory and lung infections; Infections of the lower respiratory tract; Cough with inflammatory diseases of the lungs and bronchi; Croupous pneumonia; Nosocomial pneumonia; Exacerbation of chronic pneumonia; Acute community-acquired pneumonia; Acute pneumonia; Focal pneumonia; Pneumonia abscessing; Pneumonia bacterial; Pneumonia croupy; Pneumonia of focal; Pneumonia with difficulty in sputum discharge; Pneumonia in AIDS patients; Pneumonia in children; Septic pneumonia; Chronic Obstructive Pneumonia; Chronic pneumonia; Lymphoid interstitial pneumonia

J22 Acute respiratory infection of lower respiratory tract, unspecified: Bacterial respiratory disease; Bacterial infections of the lower respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory respiratory disease;; Difficult sputum separation in acute and chronic respiratory diseases; Respiratory tract infections; Respiratory and lung infections; Lower respiratory tract infections; Infections of the lower respiratory tract; Infectious inflammation of the respiratory tract; Infectious diseases of the respiratory tract; Infectious diseases of the lungs; Infectious diseases of the respiratory system; Respiratory tract infection; Cough for colds; Pulmonary infection; Acute respiratory tract infection; Acute respiratory viral infection; Acute inflammatory airway disease; Acute respiratory disease; Respiratory infection; Respiratory and viral infections; Respiratory syncytial viral infection in young children; Respiratory diseases; Respiratory infections

J31.0 Chronic rhinitis: Rhinitis hyperplastic chronic; Polyposis rhinosinusitis; Atrophic rhinitis with crust formation; Hypertrophic rhinitis; Coryza is fetid; Rhinitis hyperplastic; Rhinitis chronic; Rhinitis chronic atrophic offensive; Rhinitis chronic atrophic simple; Rhinitis chronic hypertrophic; Exacerbation of chronic rhinitis; Chronic atrophic rhinitis; Dry rhinitis

J42 Chronic bronchitis, unspecified: Recurrent bronchitis; Asthmatic bronchitis; Asthmatic bronchitis; Bronchitis chronic; Inflammatory respiratory disease; Disease of the bronchi; Qatar smoker; Cough with inflammatory diseases of the lungs and bronchi; Exacerbation of chronic bronchitis; Chronic bronchitis; Chronic Obstructive Pulmonary Diseases; Chronical bronchitis; Chronic bronchitis of smokers; Chronic spasmodic bronchitis; Allergic bronchitis; Bronchitis allergic

J45.8 Mixed asthma: Asthma, bronchial, infectious-allergic; Infectious-allergic bronchial asthma; Infectious-allergic asthma

Composition and release form

Tablets - 1 table.

Active components: ribosomes bacterial, titrated up to 70% RNA 0.75 mg

(Including Klebsiella pneumoniae ribosomes - 3.5%, Streptococcus pneumoniae - 3.0%, Streptococcus pyogenes - 3.0 parts and Haemophilus influenzae - 0.5%)

Proteoglycans of the membrane part (including Klebsiella pneumoniae - 15 parts) 1,125 mg

Other components: silicon - 1.5 mg; Magnesium stearate - 6 mg; Sorbitol - up to 294 mg

In the blister is 4 pcs .; In the box 1 blister.

Tablets - 1 table.

Active components: ribosomes bacterial, titrated up to 70% RNA 0.25 mg

(Including Klebsiella pneumoniae ribosomes - 3.5%, Streptococcus pneumoniae - 3.0%, Streptococcus pyogenes - 3.0 parts and Haemophilus influenzae - 0.5%)

Proteoglycans of the membrane part (including Klebsiella pneumoniae - 15 parts) 0.375 mg

Other components: silicon - 0.5 mg; Magnesium stearate - 2 mg; Sorbitol - up to 98.4 mg

12 pieces in a blister; In the box 1 blister.

Granules for solution for oral administration 1 pack.

Active components: ribosomes bacterial, titrated up to 70% RNA 0.75 mg

(Including Klebsiella pneumoniae ribosomes - 3.5%, Streptococcus pneumoniae - 3.0%, Streptococcus pyogenes - 3.0 parts and Haemophilus influenzae - 0.5%)

Proteoglycans of the membrane part (including Klebsiella pneumoniae - 15 parts) 1,125 mg

Other components: polyvidone - 10 mg; D-mannitol - up to 500 mg; Silicon - 0.5 or 1.5 mg; Magnesium stearate - 2 or 6 mg; Sorbitol - up to 98.4 or 294 mg

In bags of 500 mg; In the box 4 sachets.

Description of dosage form

Tablets: round biconvex form white or almost white, odorless.

Granules: white, odorless.

Pharmachologic effect

Mode action - immunomodulating.

Pharmacodynamics

Ribosomal-proteoglycan complex of the most common pathogens of infections of the ENT organs and respiratory tract, refers to stimulators of specific and nonspecific immunity. The ribosomes that enter into it contain antigens identical to the surface antigens of bacteria, and when ingested they cause the formation of specific antibodies to these pathogens (the effect of the vaccine). Membrane proteoglycans stimulate nonspecific immunity, which is manifested in the amplification of phagocytic activity of macrophages and polynucleated leukocytes, increasing factors of nonspecific resistance. The drug stimulates the function of T- and B-lymphocytes, the production of serum and secretory immunoglobulins such as IgA, IL-1, as well as alpha and gamma interferon. This explains the preventive immunity of Ribomunylus against respiratory viral infections. Application of Ribomunil in complex therapy allows to increase efficiency and reduce the duration of treatment, significantly reduce the need for antibiotics, bronchodilators, and increase the period of remission.

Indications for the preparation Ribomunyl

Prevention and / or treatment of recurrent infections of ENT organs (otitis, sinusitis, rhinitis, pharyngitis, laryngitis, angina) and respiratory tract (chronic bronchitis, tracheitis, pneumonia, infectious-dependent bronchial asthma) in patients older than 6 months;

Prevention of recurrent infections in patients at risk (often and long-term sick, before the beginning of the autumn-winter season, especially in ecologically unfavorable regions, in patients with chronic diseases of ENT, chronic bronchitis, bronchial asthma, including in children from 6 months And elderly patients).

Contraindications

Hypersensitivity;

Autoimmune diseases.

Application in pregnancy and breastfeeding

Possible application during pregnancy and during breastfeeding, if the expected effect of therapy exceeds the potential risk to the fetus and the baby.

Side effects

Occur rarely, characterized by the following conditions:

- transient hypersalivation (at the beginning of treatment);

- allergic reactions (urticaria, angioedema, edema);

- nausea, vomiting, diarrhea.

Interaction

Not installed. You can combine with other medicines (antibiotics, bronchodilators, anti-inflammatory drugs).

Dosing and Administration

Inside (adults and children over 6 months), 1 time per day, in the morning, on an empty stomach. Single dose (regardless of age) is 3 tab. By 0.25 mg (with 1/3 of a single dose) or 1 table. On 0,75 mg (with 1 dose), or granules from 1 sachet, previously dissolved by boiled water at room temperature. In the first month of treatment and / or for prophylactic purposes, Ribomunil is taken daily 4 days a week for 3 weeks, for the next 5 months - the first 4 days of each month. Young children are advised to use granules.

Special instruction

Patients should be warned about the possibility of a transient increase in body temperature by 2-3 days, which is a manifestation of the therapeutic effect of the drug and does not usually require cessation of treatment. Increased temperature is sometimes accompanied by minor and transient symptoms of infections of ENT organs.

Storage conditions of the drug Ribomunyl

At a temperature of 15-25 ° C.

Keep out of the reach of children.

Shelf life of the drug Ribomunyl

Tablets 0.25 mg + 0.75 mg 0.25 mg + 0.75 - 5 years.

Tablets 0.75 mg + 1.125 mg 0.75 mg + 1.125 - 3 years.

Granules for solution for oral administration - 3 years.

Do not use after the expiry date printed on the package.